{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:05:35Z","timestamp":1793120735569,"version":"4.5.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"\n Importance<\/jats:title>\n Treatment options for amyotrophic lateral sclerosis (ALS) remain suboptimal. Results from a phase 2 study of reldesemtiv in ALS suggested that it may slow disease progression.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the effect of reldesemtiv vs placebo on functional outcomes in ALS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (COURAGE-ALS) was a double-blind, placebo-controlled phase 3 randomized clinical trial conducted at 83 ALS centers in 16 countries from August 2021 to July 2023. The first 24-week period was placebo controlled vs reldesemtiv. All participants received reldesemtiv during the second 24-week period with a 4-week follow-up. Two interim analyses were planned, the first for futility and the second for futility and possible resizing. This was a hybrid decentralized trial with approximately half the trial visits performed remotely and the remaining visits in the clinic. Eligible participants met criteria for definite, probable, or possible ALS with lower motor neuron signs by modified El Escorial Criteria, ALS symptoms for 24 months or less, ALS Functional Rating Scale\u2013Revised (ALSFRS-R) total score of 44 or less, and forced vital capacity of greater than or equal to 65% of predicted.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Oral reldesemtiv, 300 mg, or placebo twice daily.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was change in ALSFRS-R total score from baseline to week 24.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 696 participants screened, 207 were screen failures. A total of 486 participants (mean [SD] age, 59.4 [10.9] years; 309 male [63.6%]) were randomized to reldesemtiv (n\u2009=\u2009325) or placebo (n\u2009=\u2009161); 3 randomized patients were not dosed. The second interim analysis at 24 weeks after randomization included 256 participants. The data monitoring committee recommended that the trial should end due to futility, and the sponsor agreed. The mean (SE) group difference in the ALSFRS-R score from baseline to week 24 was \u22121.1 (0.53; 95% CI,\u2009\u22122.17 to \u22120.08;\n P<\/jats:italic>\n \u2009=\u2009.04, favoring placebo). Given excess missing data from early termination, the combined assessment assumed greater importance; it, too, failed to show a benefit from treatment with reldesemtiv (win probability was 0.44 for reldesemtiv and 0.49 for placebo, with a win ratio of 0.91; 95% CI of win ratio,\u20090.77-1.10;\n P<\/jats:italic>\n \u2009=\u2009.11).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial failed to demonstrate efficacy for reldesemtiv in slowing functional decline in ALS.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04944784<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.0241","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:59:40Z","timestamp":1742821180000},"page":"477","source":"Crossref","is-referenced-by-count":10,"title":["Reldesemtiv in Amyotrophic Lateral Sclerosis"],"prefix":"10.1001","volume":"82","author":[{"given":"Jeremy M.","family":"Shefner","sequence":"first","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute, University of Arizona, Phoenix"},{"name":"Creighton University, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit E.","family":"Cudkowicz","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genge","sequence":"additional","affiliation":[{"name":"Montreal Neurological Institute, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Hardiman","sequence":"additional","affiliation":[{"name":"Trinity College, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Al-Chalabi","sequence":"additional","affiliation":[{"name":"King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsy A.","family":"Andrews","sequence":"additional","affiliation":[{"name":"The Neurological Institute of New York, Columbia University Irving Medical Center, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Chio","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Corcia","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9ference SLA, CHU Bretonneau, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Couratier","sequence":"additional","affiliation":[{"name":"ALS Centre CHU Dupuytren, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamede","family":"de Carvalho","sequence":"additional","affiliation":[{"name":"Faculty of Medicine-University of Lisbon, Hospital de Santa Maria-CHULN, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Heiman-Patterson","sequence":"additional","affiliation":[{"name":"Neurology Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Henderson","sequence":"additional","affiliation":[{"name":"The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ingre","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Johnston","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ludolph","sequence":"additional","affiliation":[{"name":"University of, Ulm, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen e. V. (DZNE), Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Maragakis","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus S.","family":"Mora","sequence":"additional","affiliation":[{"name":"Hospital Universitario San Rafael, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Petri","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Simmons","sequence":"additional","affiliation":[{"name":"Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"van den Berg","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Zinman","sequence":"additional","affiliation":[{"name":"ALS\/Neuromuscular Clinic, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I.","family":"Malik","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Meng","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyrell J.","family":"Simkins","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wei","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy A.","family":"Rudnicki","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COURAGE-ALS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Kiernan","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schultz","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Vucic","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Matte","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"O'Connell","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Korngut","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Dionne","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Turnbull","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Schellenberg","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen","family":"Shoesmith","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Zwicker","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Salveson","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilien","family":"Bernard","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Froncois","family":"Salachas","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Danel","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Helene","family":"Soriani","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathrin","family":"Rodiger","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gro\u00dfkreutz","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Weydt","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Silani","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederica","family":"Cerri","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Calvo","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lunetta","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdelena","family":"Kusma-Kozakiewicz","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaun Francisco","family":"Vazquez-Costa","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Povedano","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Nilsson","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weber","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Young","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paganoni","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Statland","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Grogan","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Rothstein","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Oskarrson","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuen","family":"Vu","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Olney","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richared","family":"Lewis","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonnathon","family":"Katz","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Quan","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"Mccluskey","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Goyal","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantellis","family":"Pavlakis","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Swenson","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Bayat","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Goutman","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Fee","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Creigh","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Peltier","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daragh","family":"Heitzman","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Patee","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Bodkin","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margeret","family":"Owegi","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Arcilla-London","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Chahin","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafeeq","family":"Ladha","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen","family":"So","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Rezania","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rup","family":"Tandan","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kuenzler","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gwathmey","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pulley","sequence":"additional","affiliation":[{"name":"for the COURAGE-ALS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi250007r1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis.","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"noi250007r2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.nbd.2006.05.009","article-title":"Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis.","volume":"23","author":"Holzbaur","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"2","key":"noi250007r3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.expneurol.2009.02.017","article-title":"A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.","volume":"217","author":"Morrison","year":"2009","journal-title":"Exp Neurol"},{"issue":"4","key":"noi250007r4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrd3703","article-title":"Neuromuscular disorders: troponin activator improves muscle function.","volume":"11","author":"Harrison","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"noi250007r5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/jnnp-2018-320288","article-title":"Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicenter, randomised, double-blind, placebo-controlled trial.","volume":"90","author":"Al-Chalabi","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"noi250007r6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1474-4422(21)00242-8","article-title":"Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomized, double-blind, placebo-controlled phase 3 trial.","volume":"20","author":"Cudkowicz","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi250007r7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases.","volume":"18","author":"Russell","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"noi250007r8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans.","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle Nerve"},{"issue":"0","key":"noi250007r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2019.1612922","article-title":"A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.","volume":"0","author":"Shefner","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7-8","key":"noi250007r10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3109\/21678421.2013.817587","article-title":"The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS.","volume":"14","author":"Shefner","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5-6","key":"noi250007r11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3109\/21678421.2016.1148169","article-title":"A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.","volume":"17","author":"Shefner","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3-4","key":"noi250007r12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/21678421.2020.1822410","article-title":"A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS.","volume":"22","author":"Shefner","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5-6","key":"noi250007r13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/21678421.2023.2216223","article-title":"COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.","volume":"24","author":"Shefner","year":"2023","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5","key":"noi250007r14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"6","key":"noi250007r15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multiethnic reference values for spirometry for the 3- to 95-year age range: the global lung function 2012 equations.","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"noi250007r16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/21678421.2012.762930","article-title":"The Combined Assessment of Function and Survival (CAFS): a new end point for ALS clinical trials.","volume":"14","author":"Berry","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7","key":"noi250007r17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/sim.1688","article-title":"Increasing the sample size when the unblinded interim result is promising.","volume":"23","author":"Chen","year":"2004","journal-title":"Stat Med"},{"issue":"8","key":"noi250007r18","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/biom11081246","article-title":"Circulating biomarkers in neuromuscular disorders: what is known, what is new.","volume":"11","author":"Barp","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"noi250007r19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1474-4422(16)30399-4","article-title":"Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, phase 2 trial.","volume":"16","author":"Meininger","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2831901\/jamaneurology_shefner_2025_oi_250007_1746814080.74622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:01:25Z","timestamp":1747047685000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2831901"}},"subtitle":["Results From the COURAGE-ALS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.0241","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}